Clinical trials: Acute Non-Lymphocytic Leukemia
Acute Myelogenous Leukemia, High-Grade Myelodysplastic Syndrome
A Phase 2 Trial of MLN8237 in Adult Participants With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome
This is an open-label, multicenter, phase 2 study of alisertib (MLN8237) in participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
- Trial name
- NCT00830518
- Testing
- Alisertib
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Myeloid Leukemia
Study of IMC-EB10 in Participant With Leukemia
The purpose of this study is to determine if IMC-EB10 is safe for participants with leukemia, and also to determine the best dose of IMC-EB10 to give to participants.
- Trial name
- NCT00887926
- Testing
- IMC-EB10
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL)
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia.
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07205315
- Testing
- GT801 Injection
- Where
- 2 sites in China
- Volunteers
- 28 people
- Sponsor
- Grit Biotechnology
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Acute Myeloid Leukemia
Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous Leukemia
Despite the suggestions that GA and frailty indices could be used to guide therapy selection, the ability to effectively incorporate the use of GA in older patients diagnosed with AML in a real-world clinic environment has not…
- Trial name
- NCT04158726
- Testing
- modified Geriatric Assessment (mGA)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Carevive Systems, Inc.
Acute Myelogenous Leukemia
CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR
This is a phase II trial designed to test the safety and efficacy (complete response [CR]) of related donor HLA-haploidentical NK-cell based therapy for the treatment of acute myelogenous leukemia (AML).
- Trial name
- NCT03152526
- Testing
- Interventions
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Miltenyi Biotec B.V. & Co. KG
Advanced Solid Tumors, Acute Myeloid Leukemia
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical…
- Trial name
- NCT02561455
- Testing
- Gilteritinib
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult…
- Trial name
- ESVECO (NCT05587049)
- Where
- 8 sites in Colombia
- Volunteers
- 70 people
- Sponsor
- AbbVie
Acute Myelogenous Leukemia (AML)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Study of KW-2449 in Acute Myelogenous Leukemia (AML) (Protocol Number: 2449-US-002)
To determine the maximum tolerated dose of KW-2449 in people with acute myelogenous leukemia who are not candidates for approved therapy. As well, the study will determine the response rate to KW-2449.
- Trial name
- NCT00779480
- Testing
- KW-2449
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
This is a single arm, open-label study to evaluate the safety and efficacy of humanized anti-CD19 CAR-T cells in patients with relapsed or refractory B cell Malignancies.
- Trial name
- NCT04008251
- Testing
- Second generation humanized CAR-T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of targeting CD123 CAR-NK cell preparations in Relapsed/refractory acute myeloid leukemia (AML)…
- Conditions
- Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT06006403
- Testing
- CD123 targeted CAR-NK cells
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia
A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1b/2a multi-center, open-label, non-randomized study to assess the safety, tolerability and efficacy of dose-adjusted brequinar in adult subjects with acute myeloid leukemia (AML).
- Trial name
- NCT03760666
- Testing
- Brequinar/Brequinar + Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Clear Creek Bio, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)
This is an open-label, non-randomised, multi-centre phase I-II study of CHR-2797 administered orally once a day. The study involves two distinct phases: Phase I: an open-label, dose-escalating phase of the study to explore the…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT00689000
- Testing
- CHR-2797 (tosedostat): Aminopeptidase inhibitor
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Chroma Therapeutics
Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL)
CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms
One arm, open label study to assess the clinical use of Investigational Medicinal Product FCTX-CL19-1 (scientific name: Tarcidomgen Kimleucel) containing autologous anti-CD19 CAR T cells with a preliminary determination of the…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL), Large B-cell Lymphoma
- Trial name
- CARLA (NCT06593145)
- Testing
- FCTX-CL19-1 (Tarcidomgen Kimleucel)
- Where
- 2 sites in Poland
- Volunteers
- 6 people
- Sponsor
- FamiCordTx
Acute Myeloid Leukemia
PH 2 ADI-PEG 20 Acute Myeloid Leukemia
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from microbes that degrade arginine. ADI has been formulated with polyethylene glycol and has been used to treat patients that have cancers…
- Trial name
- NCT01910012
- Testing
- ADI-PEG 20
- Where
- 6 sites in United States, Taiwan
- Volunteers
- 43 people
- Sponsor
- Polaris Group
Acute Myeloid Leukemia
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
A global, multicenter, randomized, double-blind, placebo-controlled, phase III pivotal registration study, to evaluate the efficacy of APG-2575 (Lisaftoclax) combined with azacitidine (AZA) versus placebo combined with…
- Trial name
- NCT06389292
- Testing
- APG-2575(Lisaftoclax ), Azacitidine Injection
- Where
- 6 sites in China, Russia
- Volunteers
- 486 people
- Sponsor
- Ascentage Pharma Group Inc.
Bone Marrow Transplant (BMT)
HPC Offered for PRESERVE Expansion
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons.
- Trial name
- HOPE (NCT07145411)
- Testing
- Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Ossium Health, Inc.
Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
Phase 1/2 study to determine safety, tolerability, pharmacokinetics, and anti-leukemic activity of Vodobatinib (K0706) in treatment-refractory/intolerant CML
- Trial name
- NCT02629692
- Testing
- Vodobatinib (K0706) capsules
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 124 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Acute Myeloid Leukemia (AML)
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug UniCAR02-T-CD123 in patients with hematologic and…
- Trial name
- NCT04230265
- Testing
- Cyclophosphamide (Non-IMP), Fludarabine (Non-IMP), TM123 (IMP)
- Where
- 10 sites in Germany, Netherlands
- Volunteers
- 32 people
- Sponsor
- AvenCell Europe GmbH
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
A Study of Pevonedistat in Adult East Asian Participants
The purpose of this study is to evaluate the safety and tolerability of pevonedistat administered as a single agent and in combination with azacitidine in adult east Asian participants with acute myeloid leukemia (AML) or…
- Trial name
- NCT02782468
- Testing
- Pevonedistat 25 mg/m^2, Pevonedistat 44 mg/m^2, Pevonedistat 10 mg/m^2
- Where
- 9 sites in Japan, South Korea and 1 more
- Volunteers
- 23 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.